{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Cahn A"],"pubmed_abstract":["<h4>Purpose</h4>This study evaluated the safety and efficacy of inhaled nemiralisib, a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor, in patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD).<h4>Methods</h4>In this double-blind, placebo-controlled study, 126 patients (40-80 years with a post-bronchodilator forced expiratory volume in 1 sec (FEV<sub>1</sub>) ≤80% of predicted (previously documented)) were randomized 1:1 to once daily inhaled nemiralisib (1 mg) or placebo for 84 days, added to standard of care. The primary endpoint was specific imaging airway volume (siVaw) after 28 treatment days and was analyzed using a Bayesian repeated measures model (clintrials.gov: NCT02294734).<h4>Results</h4>A total of 126 patients were randomized to treatment; 55 on act"],"journal":["International journal of chronic obstructive pulmonary disease"],"pagination":["1607-1619"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8184151"],"repository":["biostudies-literature"],"pubmed_title":["An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial."],"pmcid":["PMC8184151"],"pubmed_authors":["Vos W","Wilson R","Mizuma M","Hessel EM","Van Holsbeke C","Jarvis E","De Backer J","Begg M","Leemereise C","Cui Y","Cahn A","Robertson J","Montembault M","De Backer W","Hamblin JN","Dear G"],"additional_accession":[]},"is_claimable":false,"name":"An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial.","description":"<h4>Purpose</h4>This study evaluated the safety and efficacy of inhaled nemiralisib, a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor, in patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD).<h4>Methods</h4>In this double-blind, placebo-controlled study, 126 patients (40-80 years with a post-bronchodilator forced expiratory volume in 1 sec (FEV<sub>1</sub>) ≤80% of predicted (previously documented)) were randomized 1:1 to once daily inhaled nemiralisib (1 mg) or placebo for 84 days, added to standard of care. The primary endpoint was specific imaging airway volume (siVaw) after 28 treatment days and was analyzed using a Bayesian repeated measures model (clintrials.gov: NCT02294734).<h4>Results</h4>A total of 126 patients were randomized to treatment; 55 on act","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-22T00:37:00.711Z","creation":"2022-02-10T14:35:13.871Z"},"accession":"S-EPMC8184151","cross_references":{"pubmed":["34113093"],"doi":["10.2147/COPD.S309129"]}}